Program
Program
September 11, 2026
Friday12:00 – 18:00REGISTRATION
13:00 – 13:30OFFICIAL OPENING
13:30 – 16:00
FIRST SCIENTIFIC SESSION
Personalized Oncology – Landmarks in Difficult Decisions
Moderator: Assoc. Prof. Veselin Popov MD, PhD
Personalized Oncology – Landmarks in Difficult Decisions
Moderator: Assoc. Prof. Veselin Popov MD, PhD
13:30 – 13:50Bioinformatics and Pharmacogenetics Approaches for Predictive Biomarker Discovery in Oncological Diseases Prof Aylin Koseler MD, PhD Department of Biophysics, Faculty of Medicine, Pamukkale University, Denizli, Turkey
13:50 – 14:10Methods for estimation of NK cells in cancer patients Prof. Vladimir Jurisic MD, PhD University of Kragujevac, Serbia
14:10 – 14:30Many roads to myeloma remission: making sequential choices with BMCAs and non-BMCA immunotherapies Prof. Ilina Micheva MD, PhD UMHAT “Sv. Marina”, Medical University – Varna
14:30 – 14:50Melanoma malignum – Bridging the Past, Present, and Future: Pathways to Achievement Assoc. Prof Iva Gavrilova MD, PhD USBALO, Sofia
14:50 – 15:10„Surgical management of triple negativе breast cancer“ Gerald Filip MD Ponderas Academic Hospital, Bucharest, Romania
15:10 – 15:30Management of intracranial metastasis Prof. Cuneyt Temiz MD, PhD Manisa Celal Bayar University, Medical Faculty, Dept. of Neurosurgery – Türkiye
15:30 – 15:50The Esthetic Use of Botulinum Toxins in Cancer Patients: Providing a Foundation for Future Indications Prof Marco Papagni, MD Professor at Genoa University, Aesthetic Medicine Master
15:50 – 16:20COFFEE BREAK
16:20 – 18:00
SECOND SCIENTIFIC SESSION
Innovations in Radiation and Nuclear Medicine Oncology
Innovations in Radiation and Nuclear Medicine Oncology
16:20 – 16:30Presentation by Elekta
16:30 – 16:45FLASH therapy in radiation oncology – a dream based on science and horizon of clinical practice Prof. T. Hadjieva, MD, DSc
16:45 – 17:00Modern treatment of rectal cancer – organ-preserving strategies Prof. I. Mihaylova, MD, PhD
17:00 – 17:15Expanding the boundaries of radiation therapy: beyond traditional success (supported by Astrа Zeneca) Assoc. Prof. V. Popov, MD, PhD
17:15 – 17:30Radionuclide therapy with theranostic radiopharmaceuticals in prostate cancer (supported by Novartis) Prof. E. Piperkova, MD, DSc
17:30 – 17:40 New generation helical treatments with Radixact Assoc. Prof. V. Popov, MD, PhD
17:30 – 17:40 Long-term cardiac outcomes in breast cancer patients treated with helical tomotherapy: Evaluating the applicability of 3D-based dose constraints for intensity modulated radiation therapy Prof. Julia Kirova, MD, PhD,Head of Breast Cancer Research and Treatment Group in the Department of Radiation Oncology – Paris, France
18:00 – 19:30
Business Meets Clinical Practice
18:00 – 18:20
Symposium by Novartis
““Scemblix® – A Reliable Partner for Long-Term Control of CML“
Moderator: Prof. Zh. Grudeva-Popova, MD, PhD “Clinical experience with Scemblix – efficacy and tolerability profile in a CML patient previously treated with two TKIs” – Dr. Aleksandar Yordanov
““Scemblix® – A Reliable Partner for Long-Term Control of CML“
Moderator: Prof. Zh. Grudeva-Popova, MD, PhD “Clinical experience with Scemblix – efficacy and tolerability profile in a CML patient previously treated with two TKIs” – Dr. Aleksandar Yordanov
18:20 – 18:40
Symposium by Roche
“The future today: the direction is cure”
Moderator: Prof. Zh. Grudeva-Popova, MD, PhD
Columvi + GemOx with potential for cure in 2L DLBCL – Dr. Katya Sotirova, University Hospital „St. George“ EAD, Plovdiv
“Polivy-R-CHP: advantages surpassing the 20-year standard of care in DLBCL” – Dr. Myuhtebel Adil, University Hospital „St. Ivan Rilski“, Sofia
“The future today: the direction is cure”
Moderator: Prof. Zh. Grudeva-Popova, MD, PhD
Columvi + GemOx with potential for cure in 2L DLBCL – Dr. Katya Sotirova, University Hospital „St. George“ EAD, Plovdiv
“Polivy-R-CHP: advantages surpassing the 20-year standard of care in DLBCL” – Dr. Myuhtebel Adil, University Hospital „St. Ivan Rilski“, Sofia
18:40 – 19:00
Symposium by Amgen
“Choices that leave a mark” – Prof. I. Micheva, MD, PhD
“Choices that leave a mark” – Prof. I. Micheva, MD, PhD
19:00 – 19:20
Symposium by Abbvie
“Elahere – a new standard in the treatment of ovarian cancer” – Prof. Zh. Grudeva-Popova, MD, PhD “Tepkinly changes the treatment of FL” – Prof. V. Goranova-Marinova, MD, PhD
“Elahere – a new standard in the treatment of ovarian cancer” – Prof. Zh. Grudeva-Popova, MD, PhD “Tepkinly changes the treatment of FL” – Prof. V. Goranova-Marinova, MD, PhD
19:20 – 19:30
Symposium by Аstra Zeneca
“AstraZeneca: Leadership in innovation” – Prof. E. Spasov, MD, PhD
“AstraZeneca: Leadership in innovation” – Prof. E. Spasov, MD, PhD
19:30 – 21:30WELCOME COCKTAIL
September 12, 2026
Saturday08:30 – 16:00REGISTRATION
09:00 – 10:30
THIRD SCIENTIFIC SESSION
Multiple Primary Malignant Neoplasms (MPNs) – a challenge of modern oncology
Moderator: Prof. Zh. Grudeva-Popova, MD, PhD
Multiple Primary Malignant Neoplasms (MPNs) – a challenge of modern oncology
Moderator: Prof. Zh. Grudeva-Popova, MD, PhD
09:00 – 09:15Is there a genetic predisposition to the development of MPNs? Dr. Hr. Ivanov, PhD
09:15 – 09:30MPNs in primary oncological disease Dr. G. Raycheva, MD, PhD
09:30 – 09:45MPNs in primary oncohematological disease Dr. A. Yordanov
09:45 – 10:10MPNs in primary dermatological malignant disease. BRAF (+) metastatic malignant melanoma: role of targeted therapy (supported by Pierre Fabre) Assoc. Prof. I. Gavrilova, MD, PhD
10:10 – 10:25Programming of immunity Dr. Martina Bozhkova, MD, PhD
10:30 – 11:00COFFEE BREAK
DIGITAL POSTER SESSION, FOYER, 3RD FLOOR
DIGITAL POSTER SESSION, FOYER, 3RD FLOOR
11:00 – 12:30
Business Meets Clinical Practice
11:00 – 11:30
Symposium by Swixx Biopharma
“What has changed for patients with MF in the last 10 years”
Moderator: Prof. Zh. Grudeva-Popova, MD, PhD “Early identification of treatment failure and modern new opportunities” – Dr. D. Todorieva, MD, PhD “From theory to practice (sharing clinical experience)” – Dr. T. Popova
“What has changed for patients with MF in the last 10 years”
Moderator: Prof. Zh. Grudeva-Popova, MD, PhD “Early identification of treatment failure and modern new opportunities” – Dr. D. Todorieva, MD, PhD “From theory to practice (sharing clinical experience)” – Dr. T. Popova
11:30 – 12:00
Symposium by MSD
“Pembrolizumab – current therapeutic standard and future treatment options for NSCLC” – Dr. Ivan Tonev
“Pembrolizumab – current therapeutic standard and future treatment options for NSCLC” – Dr. Ivan Tonev
12:00 – 12:30
Symposium by Johnson & Johnson
“DaraVRd in patients with newly diagnosed MM eligible for ASCT in the clinical practice of Bulgaria”
Moderator: Prof. Zh. Grudeva-Popova, MD, PhD “Summarized clinical experience with DaraVRd: data from UMHAT ‘St. George’, Plovdiv” – Dr. V. Graklanov, MD, PhD “Summarized clinical experience with DaraVRd: data from UMHAT ‘St. Marina’, Varna” – Prof. I. Micheva, MD, PhD
“DaraVRd in patients with newly diagnosed MM eligible for ASCT in the clinical practice of Bulgaria”
Moderator: Prof. Zh. Grudeva-Popova, MD, PhD “Summarized clinical experience with DaraVRd: data from UMHAT ‘St. George’, Plovdiv” – Dr. V. Graklanov, MD, PhD “Summarized clinical experience with DaraVRd: data from UMHAT ‘St. Marina’, Varna” – Prof. I. Micheva, MD, PhD
12:30 – 13:30
FOURTH SCIENTIFIC SESSION
When science leads modern therapy – the place of ‘modern’ toxicity
Moderator: Prof. V. Goranova, MD, PhD
When science leads modern therapy – the place of ‘modern’ toxicity
Moderator: Prof. V. Goranova, MD, PhD
12:30 – 12:45Clinical masks of toxicity in immunotherapy Dr. G. Raycheva, MD, PhD
12:45 – 13:00The challenge of ‘secondary immunodeficiency’ in bispecific MAbs Dr. V. Graklanov, MD, PhD
13:00 – 13:15Dermatological toxicity in modern therapy Assoc. Prof. T. Aleksiev, MD, PhD
13:15 – 13:30Is it time to talk about onconephrology? Dr. N. Dimov, MD, PhD
13:30 – 14:30LUNCH
DIGITAL POSTER SESSION, FOYER, 3RD FLOOR
DIGITAL POSTER SESSION, FOYER, 3RD FLOOR
14:30 – 16:00
FIFTH SCIENTIFIC SESSION
The young hopes in oncology
Moderator: Assoc. Prof. P. Antonov, MD, PhD
The young hopes in oncology
Moderator: Assoc. Prof. P. Antonov, MD, PhD
14:30 – 14:45The regulatory role of microRNAs in tumor angiogenesis: expression profiling and functional analysis Iliyan Pochileev
14:45 – 15:00Gene-diet interaction in oncology: from nutrigenetic data to clinical application Dr. Teodora Sokolova
15:00 – 15:15Characteristics of the plasma profile of circulating histones in patients with newly diagnosed acute myeloid leukemia Dr. Nikol Daskalova
15:15 – 15:30Immediate intravesical CT after TUR for low-grade urothelial carcinomas of the urinary bladder Dr. Denis Eshrefov
15:30 – 15:45Sentinel lymph node biopsy in skin melanoma and breast cancer – evaluation of clinical outcomes, quality of life and perception Dr. Nikolay Kiselkov
15:45 – 16:00Infrared thermography in oncodermatology: diagnostic potential and clinical applications Dr. Mariya Rodopska
16:00 – 16:30COFFEE BREAK
DIGITAL POSTER SESSION, FOYER, 3RD FLOOR
DIGITAL POSTER SESSION, FOYER, 3RD FLOOR
16:30 – 19:00
Business Meets Clinical Practice
16:30 – 17:00
Symposium by Eli Lilly
“After covalent BTK inhibition: Role of non-covalent inhibition in MCL“
Moderator: Assoc. Prof. A. Radinov, MD, PhD “MCL and BTK inhibition: From first line to relapse after BTK inhibitor – where to from here?“ – Dr. V. Graklanov, MD, PhD “Jaypirca® : mechanism of action, clinical evidence from BRUIN and positioning in MCL “ – Assoc. Prof. I. Kindekov, MD, PhD
“After covalent BTK inhibition: Role of non-covalent inhibition in MCL“
Moderator: Assoc. Prof. A. Radinov, MD, PhD “MCL and BTK inhibition: From first line to relapse after BTK inhibitor – where to from here?“ – Dr. V. Graklanov, MD, PhD “Jaypirca® : mechanism of action, clinical evidence from BRUIN and positioning in MCL “ – Assoc. Prof. I. Kindekov, MD, PhD
17:00 – 17:30
Symposium by Swixx Biopharma
“When every subsequent line matters: Trodelvy in HR+/HER2- mBC”
Moderator: Prof. N. Tsonev, MD, PhD “Data from the TROPICS-02 study” – Dr. G. Raycheva, MD, PhD “Clinical case presentation” – Dr. I. Tonev
“When every subsequent line matters: Trodelvy in HR+/HER2- mBC”
Moderator: Prof. N. Tsonev, MD, PhD “Data from the TROPICS-02 study” – Dr. G. Raycheva, MD, PhD “Clinical case presentation” – Dr. I. Tonev
17:30 – 18:10
Symposium by Astellas Pharma
“Precision and innovations in hematology and oncology”
Moderator: Dr. A. Yordanov “FLT3 as a key biomarker in AML” – Dr. Hr. Ivanova, MD, PhD “From the clinical case to the therapeutic decision in R/R FLT3m+ AML” – Dr. Ya. Petrov, MD, PhD “Xtandi – from clinical trials to real-world practice” – Dr. E. Kalekanova
“Precision and innovations in hematology and oncology”
Moderator: Dr. A. Yordanov “FLT3 as a key biomarker in AML” – Dr. Hr. Ivanova, MD, PhD “From the clinical case to the therapeutic decision in R/R FLT3m+ AML” – Dr. Ya. Petrov, MD, PhD “Xtandi – from clinical trials to real-world practice” – Dr. E. Kalekanova
18:10 – 18:30
Symposium by Pfizer
„Contemporary potential for therapeutic optimization of RRMM“ – Prof. Zh. Grudeva-Popova, MD, PhD
„Contemporary potential for therapeutic optimization of RRMM“ – Prof. Zh. Grudeva-Popova, MD, PhD
18:30 – 18:50
Symposium by Takeda
“New opportunities in the treatment of mCRC” – Dr. D. Tumbeva
“New opportunities in the treatment of mCRC” – Dr. D. Tumbeva
18:50 – 19:00
Symposium by Teva
“Lonquex® – a proven solution with history and a look into the future of G-CSF therapies” – Assoc. Prof. I. Nenova-Chilova, MD, PhD
“Lonquex® – a proven solution with history and a look into the future of G-CSF therapies” – Assoc. Prof. I. Nenova-Chilova, MD, PhD
20:00OFFICIAL DINNER – PRIMA HALL, IMPERIAL HOTEL
September 13, 2026
Sunday
09:00 – 10:30
SIXTH SCIENTIFIC SESSION
A look from the past to the achievements of the future. Pediatric solid tumors
Moderator: Prof. M. Spasova, MD, PhD
A look from the past to the achievements of the future. Pediatric solid tumors
Moderator: Prof. M. Spasova, MD, PhD
09:00 – 09:15How knowledge of genes redefines pediatric brain tumors Prof. R. Kaneva, PhD
09:15 – 09:30History of therapeutic practice in pediatric solid tumors Prof. M. Spasova, MD, PhD
09:30 – 09:45Potential of personalized medicine in children with Ewing’s Sarcoma and osteosarcoma – a single center experience Dr. Neofit Spasov, MD, PhD
09:45 – 10:00Pediatric proton therapy Bastian von Nettelbladt MD, PhD Klinik für Radioonkologie und Strahlentherapie Facharzt für Strahlentherapie – Universitätsklinikum Heidelberg
10:00 – 10:15Opportunities of modern radiotherapy in the multimodal approach for children with Ewing’s Sarcoma and osteosarcoma Dr. G. Syuleyman
10:15 – 10:30Between the diagnosis and the Child: the doctor’s difficult choice (supported by Danhson) Velislava Donkina, PhD
10:30 – 11:30
Business Meets Clinical Practice
10:30 – 10:40
Symposium by Sobi
Moderator: Prof. Zh. Grudeva-Popova, MD, PhD “Doptelet – fast and stable control over time, sharing real clinical experience” – Dr. I. Katsarska
Moderator: Prof. Zh. Grudeva-Popova, MD, PhD “Doptelet – fast and stable control over time, sharing real clinical experience” – Dr. I. Katsarska
10:40 – 10:50
Symposium by Bayer
“Personalizing treatment in mHSPC: Optimizing efficacy and quality of life with Nubeqa” – Dr. G. Raycheva, MD, PhD
“Personalizing treatment in mHSPC: Optimizing efficacy and quality of life with Nubeqa” – Dr. G. Raycheva, MD, PhD
10:50 – 11:00
Symposium by Servier
„Ivosidenib in patients with newly diagnosed AML and IDH1 mutation, ineligible for intensive therapy“ – Dr. K. Sapunarova, MD, PhD
„Ivosidenib in patients with newly diagnosed AML and IDH1 mutation, ineligible for intensive therapy“ – Dr. K. Sapunarova, MD, PhD
11:00 – 11:10
Symposium by Avanzanite
“Mitapivat 100 mg in optimizing the pathway of the patient with thalassemia” – Dr. P. Georgiev, MD, PhD
“Mitapivat 100 mg in optimizing the pathway of the patient with thalassemia” – Dr. P. Georgiev, MD, PhD
11:10 – 12:10
SEVENTH SCIENTIFIC SESSION
Moderator: Assoc. Prof. A. Botushanova, MD, PhD
Moderator: Assoc. Prof. A. Botushanova, MD, PhD
11:10 – 11:30Diagnostic challenges in nuclear medicine Assoc. Prof. A. Botushanova, MD, PhD
11:30 – 11:45Role of multiparametric MRI in the modern diagnostic algorithm for breast cancer: screening, local staging and therapeutic monitoring Dr. M. Apostolova
11:45 – 12:00Diagnostic value of 18F-FDG PET/CT in cancer of unknown primary – clinical cases with bone metastases Dr. G. Karapetkova
12:00 – 12:10Influence of the gut microbiome on the tumor microenvironment (supported by Ewopharma) Dr. Nihat Byulent
12:15 – 12:30OFFICIAL CLOSING
Scientific Committee
Chairperson
Prof. Dr. Zhanet Grudeva-Popova, MD, PhD
Members:
- Prof. Dr. Angel Uchikov, MD, DSc
- Prof. Dr. Tatyana Hadzhieva, MD, DSc
- Prof. Dr. Elena Piperkova, MD, DSc
- Prof. Dr. Radost Asenova, MD, DSc
- Prof. Dr. Ilina Micheva, MD, PhD
- Prof. Dr. Galina Kurteva, MD, PhD
- Prof. Dr. Iglika Mihaylova, MD, PhD
- Prof. Dr. Maria Spasova, MD, PhD
- Assoc. Prof. Dr. Veselin Popov, MD, PhD
- Assoc. Prof. Dr. Atanas Radinov, MD, PhD
Organizing Committee
Chairperson
Assoc. Prof. Dr. Veselin Popov, MD, PhD
Members:
- Assoc. Prof. Dr. Petar Antonov, MD, PhD
- Assoc. Prof. Dr. Albena Botushanova, MD, PhD
- Assoc. Prof. Dr. Teodor Aleksiev, MD, PhD
- Dr. Vasko Graklanov, MD, PhD
- Dr. Gabriela Raycheva, MD, PhD
- Dr. Petar Uchikov, MD, PhD
- Dr. Nikolay Dimov, MD, PhD
- Dr. Hristo Ivanov, PhD
- Dr. Aleksandar Yordanov
- Dr. Gyulhan Syuleyman
Abstract Requirements for Oral Presentation
- Deadline for submission of abstracts for oral and poster presentations – June 30, 2026.
- Deadline for submission of digital posters – September 1, 2026.
- Approval of reports and presentations by the Scientific Committee – by August 30, 2026.
- Oral presentations/reports should have a duration of up to 15 minutes.
Author requirements for submitting an abstract for an oral presentation for the Second National Conference with international participation: „Interdisciplinary Approaches in Malignant Diseases“
1. General requirements for the oral presentation abstract
- Language: Bulgarian and English
- Format: Word (.doc/.docx), Arial font, 12 pt, 1.5 line spacing
- Length: up to 300 words for the respective language
Abstract structure:
- Title (in capital letters, no abbreviations)
- Authors (first and last name, without titles)
- Affiliation (hospital, university, institution)
- Introduction / Objective
- Materials and methods
- Results
- Conclusion
- Keywords (up to 5)
2. Deadline for abstract submission
- Deadline: June 30, 2026
- Send the abstract as a DOC file, prepared according to the requirements, to: info@oncologycompass.bg
- You will receive confirmation of abstract acceptance by July 15, 2026.
3. Evaluation and selection
- All abstracts will be anonymized and evaluated by a scientific committee.
- Upon approval, the authors will be invited to prepare a presentation.
- The Scientific Committee reserves the right to change the presentation format of the abstract, informing the author accordingly.
4. Presentation requirements upon approval
- Format: PowerPoint (.ppt/.pptx) or PDF
Content:
- Title, authors, affiliation
- Introduction, objectives, methodology, results, conclusion
- Figures, tables, and graphs – clear and legible
All approved abstracts will be published in the official electronic book of abstracts. In case the author does not wish their abstract to be published, they must inform the scientific committee in writing at the email address: info@oncologycompass.bg by July 30, 2026.
Abstract Requirements for Poster Presentation
- Deadline for submission of abstracts for oral and poster presentations – June 30, 2026.
- Deadline for submission of digital posters – September 1, 2026.
- Approval of reports and presentations by the Scientific Committee – by August 30, 2026.
- Oral presentations/reports should have a duration of up to 15 minutes.
Author requirements for submitting a poster abstract for the Second National Conference with international participation: „Interdisciplinary Approaches in Malignant Diseases“
1. General requirements for the poster abstract
- Language: Bulgarian and English
- Format: Word (.doc/.docx), Arial font, 12 pt, 1.5 line spacing
- Length: up to 300 words for the respective language
Abstract structure:
- Title (in capital letters, no abbreviations)
- Authors (first and last name, without titles)
- Affiliation (hospital, university, institution)
- Introduction / Objective
- Materials and methods
- Results
- Conclusion
- Keywords (up to 5)
2. Deadline for abstract submission
- Deadline: June 30, 2026
- Send the abstract as a DOC file, prepared according to the requirements, to: info@oncologycompass.bg
- You will receive confirmation of abstract acceptance by July 15, 2026.
3. Evaluation and selection
- All abstracts will be anonymized and evaluated by a scientific committee.
- Upon approval, the authors will be invited to prepare an electronic poster.
- The Scientific Committee reserves the right to change the presentation format of the abstract, informing the author accordingly.
4. Poster requirements upon approval
- Format: PowerPoint (.ppt/.pptx) or PDF
Content:
- Title, authors, affiliation
- Introduction, objectives, methodology, results, conclusion
- Figures, tables, and graphs – clear and legible
All approved abstracts will be published in the official electronic book of abstracts. In case the author does not wish their abstract to be published, they must inform the scientific committee in writing at the email address: info@oncologycompass.bg by July 30, 2026.
Presentation Template
Download the official presentation template for the conference.
Download TemplateAbstract Book
Expect it during the conference.
